Cargando...
Tolvaptan is effective in treating patients with refractory ascites due to cirrhosis
The treatment of refractory ascites due to cirrhosis is a clinical challenge for hepatologists. Tolvaptan, a novel aquaporin modulator, was made available in Japan in 2013 for the treatment of patients with refractory ascites due to cirrhosis. Despite the potential of this drug, few reports are avai...
Guardado en:
| Publicado en: | Biomed Rep |
|---|---|
| Autores principales: | , , , , , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
D.A. Spandidos
2017
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5727763/ https://ncbi.nlm.nih.gov/pubmed/29250327 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/br.2017.1005 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|